ALNY 📈 Alnylam Pharmaceuticals - Overview

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that leverages its expertise in ribonucleic acid interference (RNAi) to discover, develop, and commercialize innovative therapeutics. The company's portfolio includes several marketed products, such as ONPATTRO (patisiran) for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, as well as AMVUTTRA, GIVLAARI, and OXLUMO, which target various rare diseases, including hATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1, respectively. These products have the potential to address significant unmet medical needs and improve the lives of patients with debilitating diseases.

Alnylam's pipeline is diverse and robust, with multiple candidates in various stages of development. The company is investigating patisiran for the treatment of transthyretin amyloidosis with cardiomyopathy, as well as cemdisiran for complement-mediated diseases. Additionally, it is developing Belcesiran for alpha-1 liver disease, Elebsiran for chronic HBV infection, and Zilebesiran for hypertension. The company is also exploring the potential of RNAi therapeutics in other areas, such as Alzheimer's disease and cerebral amyloid angiopathy with ALN-APP, and non-alcoholic steatohepatitis (NASH) with ALN-HSD. Furthermore, Alnylam is working on Fitusiran for the treatment of hemophilia, Inclisiran for hypercholesterolemia, lumasiran for advanced primary hyperoxaluria type 1, and vutrisiran for ATTR amyloidosis, which is currently in phase 3 clinical trials.

Strategic collaborations are a key component of Alnylam's business strategy. The company has partnered with Regeneron Pharmaceuticals, Inc. to develop RNAi therapeutics for diseases affecting the eye and central nervous system. It has also collaborated with Roche to develop pharmaceutical products containing zilebesiran. Moreover, Alnylam has established license and collaboration agreements with several other companies, including Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. These partnerships enable the company to leverage its expertise in RNAi technology and accelerate the development of new therapeutics. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals, Inc. is a leading player in the biopharmaceutical industry, with a strong focus on innovation and patient-centricity.

With a strong foundation in RNAi technology and a diverse portfolio of products and candidates, Alnylam Pharmaceuticals, Inc. is well-positioned to drive growth and deliver value to its stakeholders. The company's common stock is listed on the NASDAQ stock exchange under the ticker symbol ALNY, and its ISIN is US02043Q1076. As a biotechnology company, Alnylam operates in a highly competitive and rapidly evolving industry, but its commitment to innovation and patient-centricity has enabled it to establish itself as a leader in the field of RNAi therapeutics. For more information, investors and patients can visit the company's website at https://www.alnylam.com.